In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on TrovaGene (NASDAQ: TROV), with a price target of $3. The company’s shares opened today at $0.82, close to its 52-week low of $0.65.
McCarthy noted:
“Trovagene announced that the second cohort of patients in the P1b/2 study of onvansertib (PCM-075) completed dosing and the safety review committee has cleared the trial to move on to the next dose.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 41.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TrovaGene with a $2.75 average price target, implying a 235.4% upside from current levels. In a report issued on August 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $2.50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.96 and a one-year low of $0.65. Currently, TrovaGene has an average volume of 1.19M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TROV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.
